Washington University in St. Louis News & Information > WUSTL in the News >


WUSTL in the News Spotlight


(Excerpted from Hindustan Times (India), Tuesday,
Sept. 14,
2004)

U.S. cancer institute starts nanotechnology drive

The U.S. National Cancer Institute announced a new five-year plan on Monday, Sept. 13, to develop the use of tiny tools to fight cancer, saying nanotechnology just might provide the edge needed to defeat the disease.
Nanotechnology -- the design and use of devices the size of molecules -- offers new ways to detect, diagnose and to treat cancer at its earliest stages and with minimal side effects, experts told reporters.
"If we can do that then we can eliminate this disease," said Richard Smalley, a professor of nanotechnology at Rice University in Houston.
The $144.5 million plan will include the NCI Alliance for Nanotechnology in Cancer, an initiative to team up researchers, physicians, companies and not-for-profit groups to develop nanotechnology products for use in diagnosing and treating cancer.
Medicine already employs molecular size devices in the shape of natural and artificially engineered proteins such as antibodies. "What's new is we can build new nano-objects that never existed before," Smalley said.
These can be coated with homing devices such as antibodies, artificial or natural, that will find cancerous cells. They could also carry drugs to kill the cells or imaging agents to help detect cancer, said Dr. Mauro Ferrari, a special adviser to the NCI and a professor of biomedical engineering at Ohio State University.
"By doing this on a very small scale there will be different effects," said Dr. Samuel Wickline of Washington University in St. Louis.
"The possibilities are enormous for finding very small cancers far earlier than ever before and treating them with powerful drugs at the tumor site alone, while at the same time reducing any harmful side effects. This initiative will allow us to explore using this technology to its full potential."
A drug delivered using a nano-device, for example, could precisely target cancer cells without affecting healthy cells -- the way chemotherapy and radiation do now. Drugs based on monoclonal antibodies -- engineered immune system proteins -- do this but the science could be expanded, the experts said.
And liposomes, tiny capsules used to carry drugs, can be regarded as a "first generation" of nano-scale drug delivery devices.

Appeared in:

Click headline below to view news story as originally posted on an external Web site.

 | Story also ran in
11
others:
CNN International, CNN.com, Reuters, Reuters UK, The Australian, Yahoo News, Medical News Today (UK), ScienceBlog.com, Nanotechwire.com, KMOV-TV and BioWorld Today |
(Note: Links do not imply an endorsement; some sites require registration; links may change or become broken over time.)
|